SpectraCure AB (DE:2OK)
FRANKFURT:2OK
Want to see DE:2OK full AI Analyst Report?
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€3.58M
Enterprise Value€17.42M
Total Cash (Recent Filing)€13.53M
Total Debt (Recent Filing)€3.01M
Price to Earnings (P/E)―
Beta-82.99
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA low debt load relative to equity provides durable financial flexibility, reducing near-term solvency risk and enabling the company to fund R&D or clinical programs via equity or modest borrowing. This conservatism supports runway management while commercialization remains pending.
Proprietary IDOSE PlatformOwning a specialized platform (fiber-optic delivery plus real-time monitoring) is a structural competitive asset: it can create high switching costs, enable differentiated clinical outcomes, and support multiple indications over time as regulatory and clinical validation advances.
Focused Oncology Niche StrategyA concentrated go-to-market focus on minimally invasive prostate cancer therapy lets management allocate limited resources to clinical development and regulatory pathways efficiently, increasing the chance of proving the technology in a clear, addressable indication before broader rollouts.
Bears Say
Negative And Worsening Cash FlowConsistent negative operating and free cash flow with accelerating burn undermines self-financing ability, forcing reliance on external capital. Over a multi-month horizon this increases dilution and execution risk if fundraising windows tighten or capital costs rise.
Pre-commercial Revenue ProfileMinimal recurring revenue indicates the business remains pre-commercial; absent near-term product sales, the firm lacks an operating earnings buffer. This structural dependence on successful trials and approvals lengthens the path to sustainable margins and cash positive operations.
Worsening Losses And Eroding Equity BaseSteepening net losses and a materially reduced equity cushion limit long-term resilience: continued deficits will necessitate dilutive financing or asset sales. The shrinking equity base is evidence of persistent funding needs and raises sustainability concerns absent revenue inflection.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €3.58M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 13 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.